Early trial of lenalidomide after transplant for myeloma stopped early

NCT ID NCT01421927

Terminated Disease control Sponsor: University Hospital, Bordeaux Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 1 trial tested the safety of the drug lenalidomide as maintenance therapy after a reduced-intensity stem cell transplant for multiple myeloma. Only 13 people took part, and the study was terminated early. The goal was to see if lenalidomide could help prevent the cancer from coming back without causing too many side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: lenalidomide
What this could lead to: If successful, this could point toward a way to lower the chance of cancer returning after a stem cell transplant for multiple myeloma.
What could go wrong: This was a very small, early-phase trial that was terminated early, so results are limited. Lenalidomide can cause serious side effects like low blood counts and graft-versus-host disease.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

plasma cell myeloma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MULTIPLE MYELOMA

Contacts and locations

Locations

CHU Bordeaux - Hôpital Haut-Lévêque

Pessac, 33600, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.